The Company’s first vaccine uses genetically edited potatoes as the production host designed to carry the HBsAg antigen (recombinant Hepatitis B antigen) in its genome.
As the potato grows it also multiplies the HBsAg antigen it carries. Therefore tons of these specialized potatoes translates into millions of doses of Hepatitis B vaccinations produced at a very modest cost per dose. The Company has achieved a breakthrough in the controlled-
As a result the Company has successfully created a new production platform for biopharmaceuticals using its proprietary plant growth system.